Emil Iii Frei
#180,773
Most Influential Person Now
Emil Iii Frei's AcademicInfluence.com Rankings
Emil Iii Freiphilosophy Degrees
Philosophy
#11328
World Rank
#15590
Historical Rank
Logic
#8140
World Rank
#10136
Historical Rank

Download Badge
Philosophy
Why Is Emil Iii Frei Influential?
(Suggest an Edit or Addition)Emil Iii Frei's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. (2003) (1284)
- A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. (1990) (1120)
- Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. (1988) (640)
- Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. (1998) (566)
- Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. (1974) (465)
- Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). (1983) (342)
- Preclinical studies and clinical correlation of the effect of alkylating dose. (1988) (201)
- Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. (1992) (197)
- Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma (1971) (194)
- A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. (1989) (177)
- Bone marrow autotransplantation for solid tumors--prospects. (1989) (174)
- Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). (1977) (162)
- High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. (1980) (157)
- Selection bias in clinical trials. (1985) (154)
- Neoadjuvant chemotherapy in marginally resectable stage III M0 non‐small cell lung cancer: Long‐term follow‐up in 41 patients (1989) (149)
- Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III. (1987) (129)
- Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. (1975) (127)
- High-dose ifosfamide with mesna uroprotection: a phase I study. (1990) (126)
- Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. (1995) (124)
- High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. (1977) (118)
- A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. (1998) (108)
- Phase II study of topotecan in metastatic non-small-cell lung cancer. (1994) (106)
- The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. (1998) (101)
- Weekly high‐dose methotrexate‐citrovorum factor in osteogenic sarcoma. Pre‐surgical treatment of primary tumor and of overt pulmonary metastases (1977) (93)
- High-dose methotrexate in osteogenic sarcoma: a 5-year experience. (1978) (90)
- Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). (1997) (90)
- Carcinoembryonic antigen: Clinical correlation with chemotherapy for metastatic gastrointestinal cancer (1974) (85)
- Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. (1993) (83)
- A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. (1990) (82)
- Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. (1983) (81)
- An evaluation of the management of patients with cerebral metastases from malignant melanoma (1972) (73)
- New multiple‐agent chemotherapy (B‐DOPA) for advanced Hodgkin's disease (1976) (68)
- High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. (1998) (65)
- Intensive combined modality therapy for limited-stage small-cell lung cancer. (1993) (65)
- High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. (1997) (64)
- Clinical trials of hydroxyurea in patients with cancer and leukemia (1964) (63)
- Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. (1996) (59)
- Tumor necrosis factor: still a promising agent. (1989) (56)
- Serial studies of cardiac function in patients receiving adriamycin. (1978) (51)
- Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. (1999) (51)
- Lack of effectiveness of combined 5‐fluorouracil and methyl‐ccnu therapy in advanced colorectal cancer (1977) (44)
- Combination chemotherapy with adriamycin‐cyclophosphamide for advanced ovarian carcinoma (1980) (43)
- Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. (1992) (43)
- Adriamycin cardiotoxicity. (1980) (40)
- High-dose methotrexate in osteogenic sarcoma. (1981) (39)
- Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD) (1980) (38)
- Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. (1999) (35)
- High‐dose intravenous and hepatic artery infusions of thymidine (1978) (33)
- Survival of patients with localized high‐grade soft tissue sarcoma with multimodality therapy: A matched control study (1983) (32)
- Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. (1995) (31)
- Chemotherapy for head and neck cancer: progress and controversy in the management of patients with M0 disease. (1989) (31)
- A therapeutic trial of maytansine. (1978) (31)
- Adjuvant chemotherapy of osteogenic sarcoma: progress and perspectives. (1978) (29)
- High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II. (1977) (28)
- Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate‐leucovorin prior to definitive radiotherapy or surgery. (1981) (28)
- Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. (1981) (28)
- Multidisciplinary treatment for macrometastatic osteogenic sarcoma. (1976) (27)
- Pathology of surgery after induction chemotherapy: an analysis of resectability and locoregional control (1986) (25)
- Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. (1986) (22)
- Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. (1981) (22)
- Combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer. (1985) (20)
- High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results. (1981) (19)
- Hormonal perturbations in patients with testicular cancer treated with cisplatin (1992) (19)
- Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion carbogen breathing. (1993) (16)
- Pharmacokinetics and immediate effects of high-dose carmustine in man. (1986) (15)
- The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma. (1977) (15)
- A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer (2001) (14)
- High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. (1994) (14)
- Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(1)(q22) and t(1;7)(q21;q11) (1988) (13)
- New agents and combination chemotherapy of non-Hodgkin's lymphoma. (1975) (13)
- Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. (1988) (13)
- High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. (1993) (13)
- Decreased tumor oxygenation after cyclophosphamide, reoxygenation and therapeutic enhancement with a perflubron emulsion carbogen breathing. (1993) (11)
- The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials Conference. (1996) (11)
- The clinical cancer researcher--still an embattled species. (1993) (11)
- Definition and manipulation of tumor oxygenation (1994) (10)
- High‐dose therapy/stem cell support: Comparison of mice and humans (1996) (9)
- Phase I trial of combination therapy with PALA and 5-FU. (1981) (9)
- Continuous‐infusion cisplatin, 5‐fluorouracil, and bolus methotrexate in the treatment of advanced non‐small cell lung cancer (1992) (9)
- Phase I trial of bruceantin. (1979) (9)
- Non-small cell lung cancer: novel treatment strategies. (1997) (8)
- Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. (1986) (8)
- Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. (1993) (8)
- The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses (1999) (8)
- Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo (1991) (8)
- High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. (1993) (8)
- The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. (1993) (8)
- Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. (1988) (8)
- Continuous‐infusion cisplatin, 5‐fluorouracil, and leucovorin for advanced non‐small cell lung cancer (1994) (7)
- Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. (2002) (7)
- Guidelines, regulations, and clinical research. (1986) (7)
- Clinical trials of antitumor agents: experimental design and timeline considerations. (1997) (7)
- Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. (1998) (7)
- High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. (1994) (7)
- Chapter 12 – THE TOXICITY OF HIGH-DOSE BCNU WITH AUTOLOGOUS MARROW SUPPORT1 (1981) (6)
- GM‐CSF mobilized peripheral blood stem cell autografts: The DFCI/BIH experience (1992) (6)
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) for Advanced-Stage Hodgkin's Disease: CALGB 8856 (2001) (6)
- Chemotherapy (CAP) prior to radiotherapy (RT) and surgery in marginally resectable stage III M0 non-small cell lung cancer. (1985) (5)
- Clinical evaluation of local hyperthermia by focused ultrasound (abstract) (1982) (5)
- Quality of life in cancer patients: clinical considerations and perspectives. (1990) (4)
- A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies (2001) (4)
- 5‐Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer (1975) (4)
- Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study (2005) (3)
- Testing for doxorubicin cardiotoxicity. (1979) (3)
- Dose response for adjuvant chemotherapy of breast cancer: experimental and clinical considerations. (1989) (2)
- GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: Two protocols (1991) (2)
- Prolonged survival of renal allograft in rats by methotrexate-albumin conjugates as immunosuppressive therapy. (2008) (2)
- Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11) (1988) (2)
- Limb preservation in osteogenic sarcoma: a preliminary report. (1977) (2)
- P-425 A Phase I trial of extrapleural pneumonectomy and intraoperative,bicavitary, hyperthermic cisplatin lavage with intravenous sodium thiosulfate protection for patients with malignant pleural mesothelioma (2005) (1)
- The modulation of alkylating agents. (1991) (1)
- Neo-adjuvant infusion Cisplatin, 5-FU and high-dose leucovorin for squamous cell carcinoma of the head and neck (SCCHN): high rates of complete response (CR) and definitive radiotherapy as primary site management (1994) (1)
- Neo-Adjuvant Cisplatin, 5-Fluorouracil and high-dose Leucovorin for advanced head and neck cancer : response, toxicity, survival and comparison with historical controls (1991) (1)
- Impact of Chemotherapy on Osteogenic Sarcoma (1979) (0)
- HIGH DOSE METHOTREXATE (HDM) WITH CITROVORUM (CF) RESCUE IN THE MANAGEMENT OF BONE TUMORS (1974) (0)
- ThymidineRequirementsfor the Rescueof PatientsTreated with High-DoseMethotrexat& (2006) (0)
- Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer (2003) (0)
- Randomized clinical trials and other approaches in clinical research (1994) (0)
- High-Dose Chemotherapy III Breast Cancer (1991) (0)
This paper list is powered by the following services: